Endo License and Development Agreement - Additional Information (Detail) (USD $)	0 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended							6 Months Ended
	Jun. 25, 2014	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014 Milestone	Jun. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Jan. 23, 2014	May 31, 2012	Jan. 17, 2012	Jan. 31, 2014 Clinical Trials One [Member]	Jun. 30, 2014 Clinical Trials Two [Member]	Jun. 30, 2014 Endo License and Development Agreement [Member]
Revenue Recognition, Milestone Method [Line Items]
Non-refundable payment received										$ 30,000,000
Potential milestone payments on intellectual property rights				15,000,000
Potential milestone payment received clinical development		20,000,000		20,000,000							10,000,000	10,000,000
Potential milestone payment receivable regulatory events				60,000,000
Payment receivable on achievement of potential sales milestones		55,000,000		55,000,000
Number of potential sales milestones				4
Recognized up-front payment allocated to the license				15,600,000
Recognized up-front payment to clinical trial material and development services				14,400,000
Upfront payment				30,000,000
Estimated amount recognized against clinical services deliverable				1,800,000		6,300,000	5,200,000
Deferred revenue income of the research and development activities		1,100,000		1,100,000									10,800,000
Term of Endo Agreement				10 years
Extended patent on drug delivery technology				2020 to 2027
Potential milestone payments on issuance of patent									15,000,000
Total rate of reimbursable contractor costs borne				50.00%									50.00%
Reimbursement rate of costs by Endo to the company as per agreement													100.00%
Percentage of credit against potential future milestone													50.00%
Deffered revenue recognized during the period				3,500,000
Milestone payment regarding licensing agreement	10,000,000							10,000,000
Receivable and corresponding contract revenue	$ 10,000,000	$ 10,674,895	$ 1,908,949	$ 21,958,728	$ 3,530,926